Strategic Science & Technologies is a privately-held technology company that focuses on commercializing a novel, patented transdermal administration formula. Its technology is used to formulate known pharmaceutical active ingredients that have a faster onset of action, delivers molecules across the skin in therapeutic areas including pain, and treat sexual disorders that enable physicians to treat various diseases with the support of technology.

Nippon Shinyaku Co., Ltd. engages in the manufacture and sale of pharmaceuticals and foodstuffs. Its operations are carried out through the Pharmaceuticals and Functional Food divisions. The Pharmaceuticals division develops and distributes drugs that treat urological diseases, inflammation, allergies, hematological malignancies, cardiovascular and metabolic diseases, and gastrointestinal disorders. The Functional Food division manufactures and supplies health food ingredients, preservatives, protein preparations, nutritional ingredients, seasonings and spices, and sterilization cleaning agents. The company was founded on November 20, 1911 and is headquartered Kyoto, Japan.

Medrx Co. Ltd. engages in the business of pharmaceutical drug development based on the transdermal absorption. It develops new value-added medicines by the drug formulation technology based on ILTS (Ionic Liquid Transdermal System), a unique technologies using ionic liquid and unique transdermal drug delivery technology using nano-sized colloid transdermal system for drugs. The company was founded by Masayoshi Matsumura on January 15, 2002 and is headquartered in Higashikagawa, Japan.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Jiangyin Bent Samuelson Life Science Research Institute Co., Ltd., established on 2013-07-03, Business scope includes pharmaceutical,Medical Device Research,to develop,Technical Services,technology transfer;Healthcare Management Services;cosmetic,biochemical reagents,Peptide and protein pharmaceutical intermediates,disinfection products(The above items do not contain dangerous goods),hygiene products,Sales of Medical Devices;Self-operated and agent import and export business of various commodities and technologies,Except for commodities and technologies that are restricted by the state to be operated by enterprises or prohibited from import and export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

CellGenTech, Inc. engages in the research and development of drugs for new gene therapy and regenerative medicine. It offers adipocyte-based medicine, technology for the development of gene/cell therapies. It also provides protein supplemental therapy solutions in the areas of hereditary diseases; orphan diseases; intractable diseases, such as lysosome and hemophilia; diabetics; arteriosclerotic diseases, and cancer or degenerative neuropathies. The company was founded by Masayuki Aso on October 20, 2003 and is headquartered in Chiba, Japan.

Fujisawa Pharmaceutical Co. Ltd. develops, manufactures and markets pharmaceuticals and medical products. The Group's principal activity is the manufacture and sale of pharmaceuticals, medical equipment and supplies, home care products, chemicals and animal health products. Pharmaceuticals (ethical drugs, OTC drugs, toilet goods) accounted for 91% of fiscal 2002 revenues and other operations (food additives, industrial chemicals, animal drugs, research and clinical reagents). It was founded in 1894 and was headquartered in Osaka, JP

Sp.El. specializes in industrial automation projects that helps in automating any type of industrial machine.

Kringle Pharma, Inc., a biopharmaceutical company, develops pharmaceutical products based on its research on hepatocyte growth factor (HGF) and NK4. Its HGF has the regenerative healing ability in regard to liver cells, as well as various cells and organs; and NK4 is a bi-functional molecule, which inhibits the invasion and metastasis of tumor cells as an HGF-antagonist, as well as possesses antiangiogenic activity. The company’s pipeline includes recombinant human HGF for the treatment of acute renal failure, skin ulcers, and CNS diseases; and recombinant human NK4 and NK4 gene drugs for cancer therapy. Kringle Pharma, Inc. was founded in 2001 and is based in Toyonaka, Japan.

Pharmacia & Upjohn Co. LLC, a subsidiary of Pfizer Inc., is a company headquartered in Bingham Farms, MI, that manufactures and supplies pharmaceutical goods.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

SunTen Phytotech Co., Ltd., an herbal-based biotechnology company, develops botanical medicines and functional dietary products. Its products include SB221, a mixture of traditional Chinese herbal extracts for the treatment and prevention of vascular endothelial dysfunction-related diseases; STA36, a botanical composition for the adjuvant treatment of chronic asthma; STD052, a partially purified herbal material for gastrointestinal, cardiovascular, and kidney diseases; and STD06, an active component for various skin disorders and wound healing.

Maruho Co., Ltd. engages in the research, development, manufacture, and marketing of pharmaceutical products. It specializes in the production of dermatology and topical drugs. Its products include Hirudoid Cream, Eksalb, Rozex Gel, Casal Cream, Farom Tablets, and Telgin G Dry Syrup. The company was founded by Eikuma Koba in July 1915 and is headquartered in Osaka, Japan.

R-Tech Ueno Ltd. engages in the research and development, manufacture and sale of pharmaceutical products. It operates through the following business divisions: New Pharmaceutical Research and Development, Pharmaceutical Manufacture and Sale, and Pharmaceutical Development Support and Contract Manufacturing Services. The New Pharmaceutical Research and Development business provides development for unmet medical needs area, orphan drug area, and anti-aging area. The Pharmaceutical Manufacture and Sale business handles the manufacture and sale of Rescula Eye Drops for glaucoma and ocular hypertension. The Pharmaceutical Development Support and Contract Manufacturing Services business covers the manufacture and sale of AMITIZA capsules for chronic idiopathic constipation. It also accepts contract manufacturing of eye drops, liquid drugs and liquid-filled hard capsules. The company was founded by Ryuji Ueno and Sachiko Kuno in September 1989 and is headquartered in Tokyo, Japan.

Maruishi Firm founded in Awajimachi, Higashi-ku, Osaka.

Terumo is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare.

BRH Medical specializes in developing and marketing medical devices for the treatment of chronic wounds. The company’s products implement a patent protected technology that combines therapeutic ultrasound and electrostimulation, together with advanced database software to generate excellent results in clinical applications. BRH Medical implements the novel technology in a range of products, advancing the treatment of chronic wound care to unsurpassed levels of success. BRH Medical was founded on 2011 and is headquartered in Jerusalem, Israel.

Nishida KK is a private company headquartered in Japan involved in gasoline service stations.

Operates as a clinical stage biopharmaceutical company